InvestorsHub Logo
Followers 137
Posts 22855
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 08/31/2014 8:54:16 AM

Sunday, August 31, 2014 8:54:16 AM

Post# of 2206
Upcoming milestones and value driving events
Hepatitis C first-in-man Phase I/IIa trial to commence dosing in Q1 2014
Interim safety data – Q2 & Q3 Interim efficacy data – Q3 & Q4
Advancement of lung cancer program
Toxicology studies to be undertaken in 2014
Phase I/IIa clinical trial aimed to commence in late 2014
Progress on Calimmune’s HIV/AIDS clinical trial throughout 2014
Additional licensing agreements for other disease areas
Progress on other pipeline programs as resources allow

http://www.asx.com.au/spotlight/london/documents/presentations/Benitec_Biopharma_london.pdf

Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News